Ipralin
Generic Name
Ipratropium Bromide
Manufacturer
Example Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| ipralin 25 mg respirator solution | ৳ 20.00 | N/A |
Description
Overview of the medicine
Ipratropium bromide is an anticholinergic bronchodilator used for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is administered via nebulization. The specified 25 mg strength is significantly higher than typical single doses (0.25-0.5 mg) and requires careful medical guidance.
Uses & Indications
Dosage
Adults
The typical dose of ipratropium bromide respirator solution for adults is 0.25 mg to 0.5 mg, 3-4 times daily. However, for a 25 mg solution, specific instructions from a healthcare professional are crucial due to the significantly higher stated strength in this product. Patients should dilute as instructed or use pre-diluted unit-dose vials. The 25 mg strength indicated on this product is highly unusual for a single nebulizer dose; verify with physician.
Elderly
No specific dose adjustments needed, but monitor for anticholinergic side effects. Refer to adult dosage, but again, given the 25 mg stated strength, strict medical guidance is essential.
Renal_impairment
No specific dose adjustments required, as renal excretion of the systemically absorbed portion is minor. However, medical advice for a 25 mg solution is crucial.
How to Take
Administer via nebulizer. Ensure proper dilution if necessary, and follow instructions from your healthcare provider or the product leaflet. Do not swallow.
Mechanism of Action
Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, when inhaled, produces local bronchodilation by blocking muscarinic cholinergic receptors in the bronchial smooth muscle.
Pharmacokinetics
Onset
15 minutes
Excretion
Primarily excreted renally (25%) and fecally (75%) as unchanged drug and metabolites.
Half life
Approximately 1.6 hours (for systemically absorbed portion)
Absorption
Poorly absorbed systemically from the lung and gastrointestinal tract. Systemic bioavailability is very low (approx. 7%).
Metabolism
Partially metabolized in the liver to inactive metabolites.
Side Effects
Contraindications
- •Hypersensitivity to ipratropium bromide, atropine, or its derivatives.
- •Hypersensitivity to any excipients in the formulation.
Drug Interactions
Beta-adrenergics
May be used concurrently with beta-adrenergics; synergistic bronchodilation may occur.
Other anticholinergics
Concurrent administration with other anticholinergic drugs may lead to additive anticholinergic effects, increasing the risk of side effects like dry mouth, urinary retention, and blurred vision.
Storage
Store below 30°C. Protect from light. Do not freeze. Keep out of reach of children.
Overdose
Acute overdose is unlikely due to the local action and poor systemic absorption. Potential symptoms of overdose may include dry mouth, blurred vision, and tachycardia. Treatment is symptomatic and supportive.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of teratogenicity. Use during pregnancy only if clearly needed. It is not known whether ipratropium bromide is excreted in human milk; use with caution in nursing mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from manufacturing date
Availability
Pharmacies, Hospitals
Approval Status
Approved by DGDA (Bangladesh)
Patent Status
Off-patent
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
